Does the media favor MDXH or SKYE?

In the previous week, Skye Bioscience had 3 more articles in the media than MDxHealth. MarketBeat recorded 4 mentions for Skye Bioscience and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that MDxHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer KYNB or SKYE?

In the previous week, Skye Bioscience had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 4 mentions for Skye Bioscience and 3 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.67 beat Skye Bioscience's score of -0.55 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable valuation & earnings, SKYE or CNTX?

Context Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$10.16 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is SKYE or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -329.08% -201.79% Context Therapeutics N/A -82.06% -72.74%

Does the media refer more to SKYE or CNTX?

In the previous week, Skye Bioscience had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Skye Bioscience and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SKYE or ALGS?

In the previous week, Skye Bioscience had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Skye Bioscience and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SKYE or GOSS?

In the previous week, Skye Bioscience and Skye Bioscience both had 4 articles in the media. Gossamer Bio's average media sentiment score of 0.11 beat Skye Bioscience's score of -0.55 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Skye Bioscience (SKYE) Competitors

$1.76 +0.20 (+12.42%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.79 +0.03 (+1.42%)

As of 09/18/2026 07:30 PM Eastern

Compare

SKYE vs. MDXH, KYNB, CNTX, ALGS, and GOSS

Should you buy Skye Bioscience stock or one of its competitors? Skye Bioscience's main competitors and comparable companies include MDxHealth (MDXH), Kyntra Bio (KYNB), Context Therapeutics (CNTX), Aligos Therapeutics (ALGS), and Gossamer Bio (GOSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Skye Bioscience compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Skye Bioscience has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Skye Bioscience	N/A	-329.08%	-201.79%

MDxHealth presently has a consensus target price of $2.17, suggesting a potential upside of 243.92%. Skye Bioscience has a consensus target price of $64.00, suggesting a potential upside of 3,526.06%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

MDxHealth has higher revenue and earnings than Skye Bioscience. MDxHealth is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.29	-$33.52M	-$0.72	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

21.1% of Skye Bioscience shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MDxHealth has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market.

In the previous week, Skye Bioscience had 3 more articles in the media than MDxHealth. MarketBeat recorded 4 mentions for Skye Bioscience and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that MDxHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

MDxHealth beats Skye Bioscience on 8 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Kyntra Bio has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.9, suggesting that its stock price is 190% more volatile than the broader market.

In the previous week, Skye Bioscience had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 4 mentions for Skye Bioscience and 3 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.67 beat Skye Bioscience's score of -0.55 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Kyntra Bio currently has a consensus target price of $37.25, indicating a potential upside of 426.87%. Skye Bioscience has a consensus target price of $64.00, indicating a potential upside of 3,526.06%. Given Skye Bioscience's higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Kyntra Bio has a net margin of 2,199.13% compared to Skye Bioscience's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Skye Bioscience	N/A	-329.08%	-201.79%

Kyntra Bio has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.45	$183.45M	$45.30	0.16
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kyntra Bio beats Skye Bioscience on 12 of the 16 factors compared between the two stocks.

How does Skye Bioscience compare to Context Therapeutics?

Skye Bioscience (NASDAQ:SKYE) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Skye Bioscience currently has a consensus price target of $64.00, suggesting a potential upside of 3,526.06%. Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,575.27%. Given Skye Bioscience's higher possible upside, equities research analysts plainly believe Skye Bioscience is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Context Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Skye Bioscience had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Skye Bioscience and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Skye Bioscience has a beta of 2.9, suggesting that its share price is 190% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Context Therapeutics' return on equity of -82.06% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Context Therapeutics	N/A	-82.06%	-72.74%

Summary

Context Therapeutics beats Skye Bioscience on 7 of the 13 factors compared between the two stocks.

How does Skye Bioscience compare to Aligos Therapeutics?

Skye Bioscience (NASDAQ:SKYE) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Aligos Therapeutics has higher revenue and earnings than Skye Bioscience. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A
Aligos Therapeutics	$2.19M	14.93	-$24.19M	-$7.30	N/A

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Skye Bioscience currently has a consensus price target of $64.00, indicating a potential upside of 3,526.06%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 634.73%. Given Skye Bioscience's higher probable upside, equities research analysts clearly believe Skye Bioscience is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Skye Bioscience had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Skye Bioscience and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.00 beat Skye Bioscience's score of -0.55 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Skye Bioscience has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Skye Bioscience has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

Summary

Aligos Therapeutics beats Skye Bioscience on 11 of the 16 factors compared between the two stocks.

How does Skye Bioscience compare to Gossamer Bio?

Skye Bioscience (NASDAQ:SKYE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Skye Bioscience has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Gossamer Bio	-235.00%	N/A	-112.04%

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Skye Bioscience has a beta of 2.9, suggesting that its share price is 190% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Skye Bioscience and Skye Bioscience both had 4 articles in the media. Gossamer Bio's average media sentiment score of 0.11 beat Skye Bioscience's score of -0.55 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Skye Bioscience currently has a consensus price target of $64.00, suggesting a potential upside of 3,526.06%. Gossamer Bio has a consensus price target of $256.00, suggesting a potential upside of 2,285.83%. Given Skye Bioscience's higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Skye Bioscience has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A
Gossamer Bio	$53.29M	0.59	-$170.37M	-$56.00	N/A

Summary

Skye Bioscience and Gossamer Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.81M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.17	14.23	275.49	25.40
Price / Sales	N/A	1,434.96	642.70	86.83
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.35	15.45	10.46	6.33
Net Income	-$55.92M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-13.48%	-1.21%	0.59%	1.12%
1 Month Performance	-21.32%	-3.29%	-1.74%	-2.39%
1 Year Performance	-94.48%	37.74%	18.13%	5.35%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	3.2127 of 5 stars	$1.77 +12.4%	$64.00 +3,526.1%	-94.5%	$7.81M	N/A	N/A	12	News Coverage Positive News
MDXH MDxHealth	2.1118 of 5 stars	$0.67 -4.8%	$2.17 +221.8%	-84.8%	$35.01M	$107.88M	N/A	300	News Coverage Positive News
KYNB Kyntra Bio	3.8759 of 5 stars	$7.77 -3.2%	$36.00 +363.3%	N/A	$32.51M	$6.44M	0.17	570	News Coverage Analyst Upgrade Gap Up
CNTX Context Therapeutics	2.3865 of 5 stars	$0.36 +3.8%	$6.17 +1,592.3%	-62.0%	$32.25M	N/A	N/A	7	News Coverage
ALGS Aligos Therapeutics	2.1854 of 5 stars	$4.99 -1.0%	$38.50 +671.5%	-45.8%	$31.47M	$2.19M	N/A	90	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. MDXH, KYNB, CNTX, ALGS, and GOSS

How does Skye Bioscience compare to MDxHealth?

Summary

How does Skye Bioscience compare to Kyntra Bio?

Summary

How does Skye Bioscience compare to Context Therapeutics?

Summary

How does Skye Bioscience compare to Aligos Therapeutics?

Summary

How does Skye Bioscience compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. MDXH, KYNB, CNTX, ALGS, and GOSS

How does Skye Bioscience compare to MDxHealth?

Is MDXH or SKYE more profitable?

Do analysts recommend MDXH or SKYE?

Which has higher valuation and earnings, MDXH or SKYE?

Do institutionals and insiders hold more shares of MDXH or SKYE?

Which has more risk & volatility, MDXH or SKYE?

Does the media favor MDXH or SKYE?

Summary

How does Skye Bioscience compare to Kyntra Bio?

Which has more risk and volatility, KYNB or SKYE?

Does the media prefer KYNB or SKYE?

Do analysts recommend KYNB or SKYE?

Is KYNB or SKYE more profitable?

Which has higher earnings and valuation, KYNB or SKYE?

Do insiders & institutionals believe in KYNB or SKYE?

Summary

How does Skye Bioscience compare to Context Therapeutics?

Do analysts rate SKYE or CNTX?

Which has preferable valuation & earnings, SKYE or CNTX?

Does the media refer more to SKYE or CNTX?

Which has more volatility & risk, SKYE or CNTX?

Do insiders and institutionals believe in SKYE or CNTX?

Is SKYE or CNTX more profitable?

Summary

How does Skye Bioscience compare to Aligos Therapeutics?

Which has preferable earnings & valuation, SKYE or ALGS?

Do insiders & institutionals have more ownership in SKYE or ALGS?

Do analysts rate SKYE or ALGS?

Does the media favor SKYE or ALGS?

Is SKYE or ALGS more profitable?

Which has more risk & volatility, SKYE or ALGS?

Summary

How does Skye Bioscience compare to Gossamer Bio?

Is SKYE or GOSS more profitable?

Do institutionals & insiders hold more shares of SKYE or GOSS?

Which has more risk & volatility, SKYE or GOSS?

Does the media favor SKYE or GOSS?

Do analysts prefer SKYE or GOSS?

Which has preferable valuation & earnings, SKYE or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools